These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 10417291)

  • 61. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
    Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
    Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi.
    Falchi M; Bataille V; Hayward NK; Duffy DL; Bishop JA; Pastinen T; Cervino A; Zhao ZZ; Deloukas P; Soranzo N; Elder DE; Barrett JH; Martin NG; Bishop DT; Montgomery GW; Spector TD
    Nat Genet; 2009 Aug; 41(8):915-9. PubMed ID: 19578365
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genetics: what advice for patients who present with a family history of melanoma?
    Newton Bishop JA; Gruis NA
    Semin Oncol; 2007 Dec; 34(6):452-9. PubMed ID: 18083368
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inferring linkage disequilibrium between a polymorphic marker locus and a trait locus in natural populations.
    Luo ZW; Tao SH; Zeng ZB
    Genetics; 2000 Sep; 156(1):457-67. PubMed ID: 10978308
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hereditary cutaneous melanoma.
    Platz A; Ringborg U; Hansson J
    Semin Cancer Biol; 2000 Aug; 10(4):319-26. PubMed ID: 10966854
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Loss of heterozygosity at chromosome 9p21 (INK4-p14ARF locus): homozygous deletions and mutations in the p16 and p14ARF genes in sporadic primary melanomas.
    Kumar R; Smeds J; Lundh Rozell B; Hemminki K
    Melanoma Res; 1999 Apr; 9(2):138-47. PubMed ID: 10380936
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interobserver concordance in discriminating clinical atypia of melanocytic nevi, and correlations with histologic atypia.
    Meyer LJ; Piepkorn M; Goldgar DE; Lewis CM; Cannon-Albright LA; Zone JJ; Skolnick MH
    J Am Acad Dermatol; 1996 Apr; 34(4):618-25. PubMed ID: 8601651
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Classifying melanocytic tumors based on DNA copy number changes.
    Bastian BC; Olshen AB; LeBoit PE; Pinkel D
    Am J Pathol; 2003 Nov; 163(5):1765-70. PubMed ID: 14578177
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Genetic counseling and DNA testing in patients with increased risks for malignant melanoma].
    Itin PH; Fistarol SK
    Ther Umsch; 2003 Aug; 60(8):469-72. PubMed ID: 14502854
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prediction of histologic melanocytic dysplasia from clinical observation.
    Roush GC; Dubin N; Barnhill RL
    J Am Acad Dermatol; 1993 Oct; 29(4):555-62. PubMed ID: 8408790
    [TBL] [Abstract][Full Text] [Related]  

  • 71. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 72. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
    Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
    J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CDKN2A mutations in melanoma families from Uruguay.
    Larre Borges A; Cuéllar F; Puig-Butillé JA; Scarone M; Delgado L; Badenas C; Milà M; Malvehy J; Barquet V; Núñez J; Laporte M; Fernández G; Levrero P; Martínez-Asuaga M; Puig S
    Br J Dermatol; 2009 Sep; 161(3):536-41. PubMed ID: 19523171
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessment of clonality in melanocytic nevi.
    Hui P; Perkins A; Glusac E
    J Cutan Pathol; 2001 Mar; 28(3):140-4. PubMed ID: 11168766
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
    Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
    Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical and epidemiological aspects of subtypes of melanocytic nevi (Flat nevi, Miescher nevi, Unna nevi).
    Witt C; Krengel S
    Dermatol Online J; 2010 Jan; 16(1):1. PubMed ID: 20137743
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.
    Kvaskoff M; Whiteman DC; Zhao ZZ; Montgomery GW; Martin NG; Hayward NK; Duffy DL
    Twin Res Hum Genet; 2011 Oct; 14(5):422-32. PubMed ID: 21962134
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
    Puig S; Ruiz A; Castel T; Volpini V; Malvehy J; Cardellach F; Lynch M; Mascaro JM; Estivill X
    Hum Genet; 1997 Dec; 101(3):359-64. PubMed ID: 9439668
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
    Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
    Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Acquired melanocytic nevi in childhood and familial melanoma.
    Vredenborg A; Böhringer S; Boonk SE; Gruis NA; Out-Luijting C; Kukutsch NA; Bergman W
    JAMA Dermatol; 2014 Jan; 150(1):35-40. PubMed ID: 24196164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.